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Abstract
Background: The pharmacokinetics of proton pump inhibitors (PPIs) may be affected by food intake. We aimed to
evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole.
Setting: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clinical trials.
Method: Subjects were evaluated to determine the effect of a high-fat breakfast on the pharmacokinetics of
omeprazole (n = 36), rabeprazole (n = 69), and pantoprazole (n = 81).
Main outcome measure: Drug plasma concentrations were measured using high-performance liquid chromatography
coupled to mass spectrometry.
Results: Food affected the pharmacokinetics of omeprazole (increased Tmax and decreased AUC and Cmax), pantoprazole
(increased Tmax and decreased AUC), and rabeprazole (increased Tmax, Cmax and half-life). Food increased variability in Tmax
for all 3 drugs, delaying absorption around 3 to 4 h and until 20 h in some subjects.
Conclusion: As food delays the absorption of PPIs and increases their variability, it would be better to administer these
drugs under fasting conditions.
Trial registration: European Union Drug Regulating Authorities Clinical Trials Database: EudraCT: 2004–003863-59
(registration date 05/MAR/2004), EudraCT 2006–001162-17 (registration date 17-MAR-2006), EudraCT: 2007–002489-37
(registration date 12-JUN-2007), EudraCT: 2007–002490-31 (registration date 12-JUN-2007), EudraCT: 2010–024029-19
(registration date 23-NOV-2010).
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Bulleted statements on the impact of the research
findings on patients, pharmacy or clinical practice
1. To be more effective, it is recommended to
administer PPIs better under fasting conditions.
2. More effective administration could improve
patient outcomes.
Background
Proton pump inhibitors (PPIs) are used for the treatment
of acid-related diseases such as gastric and duodenal ul-
cers, gastroesophageal reflux disease, non-erosive reflux
disease, and Zollinger-Ellison syndrome. They are also
used in combination with antibiotics for the eradication of
Helicobacter pylori [1].
PPIs inhibit gastric H+/K+-ATPase pump activity,
resulting in potent acid inhibition. However, the ability
of PPIs to suppress gastric acid varies widely between in-
dividuals. Several factors contribute to this phenomenon,
including the considerable variation in the oral bioavailabil-
ity of PPIs, the need for the ATPase pumps to be activated
by food, the influence of Helicobacter pylori–associated gas-
tritis, and genetic variation in enzyme activity [2]. Indeed,
drug formulation, food intake, and single-nucleotide poly-
morphisms in cytochrome P450 (CYP) 2C19 enzyme also
influence PPIs pharmacokinetic parameters [3–5]. Thus,
the time to maximum plasma concentration (Tmax) varies
from 1 h to 5 h depending on the drug formulation and/or
food effect [3, 4].
Tytgat et al. reported that the bioavailability of PPIs was
markedly affected by food intake [6]; consequently, PPIs
should be taken under fasting conditions. However, PPIs
prescribing information is controversial, since some authors
state that in case of omeprazole and rabeprazole the con-
comitant ingestion of food does not affect their bioavailabil-
ity [7, 8], whereas others state that omeprazole should be
taken at least 1 h before a meal [9]. The recommendations
for pantoprazole depend on the formulation: tablets could
be taken regardless of meal timing, but oral suspension
should be taken 30min before a meal [10]. To date, there
was some evidence that taking PPIs with food affected their
absorption. However, until now it has not been rigorously
evaluated. This study provides the necessary evidence.
Aim of the study
This study aimed to evaluate the influence of food on
the pharmacokinetic parameters of three PPIs (omepra-
zole, rabeprazole and pantoprazole) and to determine
whether food is more relevant for any of them.
Methods
Study design
The study population comprised 186 healthy Caucasian
adult volunteers from 6 single-dose bioequivalence
clinical trials with pantoprazole (40 mg, enteric-coated
tablets), rabeprazole (20 mg, enteric-coated tablets), and
omeprazole (40 mg, oral capsules). The bioequivalence
clinical trials were phase I, randomized, open-label,
crossover, single-centre, with two periods separated by a
7-day washout stage. Subjects were randomised to one
of the two treatment sequences, RT or TR where R was
the reference formulation and T was the test formula-
tion. Each of the clinical trial was crossover for evalu-
ation of a test formulation compared to a reference
formulation either under fed or fasting conditions. Dif-
ferent subjects participated in each trial, but in case of
omeprazole, that 35 of 36 volunteers were the same for
the trials under fed and fasting conditions. The treat-
ments were allocated in a balanced manner on every in-
clusion day (blocks of 4 subjects). Our study adheres to
CONSORT guidelines.
Considering the expected intrasubject variability for
each study, using a multiplicative model, sample size
was calculated to reject a difference between both for-
mulations of 20%, with a power of 80% and an alpha
error of 0.05, according to the bioequivalence ap-
proaches habitually accepted by the Health Authorities
(acceptance limits of 0.8–1.25).
From those 186 healthy volunteers, 81 subjects re-
ceived pantoprazole (36 under fasting conditions,
EudraCT: 2004–003863-59; and 45 with food, EudraCT
2006–001162-17), 69 received rabeprazole (35 under
fasting conditions, EudraCT: 2007–002489-37; and 34
with food, EudraCT: 2007–002490-31) and 36 received
omeprazole (35 under fasting conditions and 36 with
food; EudraCT: 2010–024029-19). In case of omeprazole,
35 volunteers were the same for both trials. In the trials
with food, volunteers fasted for 10 h, the breakfast was
taken in 20 min (between 30 and 10min previous to
dosing) and the drug was administered 10min after the
end of breakfast. The meal had a high fat content (50–
60% of total caloric content of the meal) and high calorie
count (approximately 800 to 1000 kcal) according to
EMA [11] and FDA [12] guidelines.
The inclusion criteria were as follows: non-smoking
male and female volunteers, age 18 to 55 years, body
mass index (BMI) within the 18.5–30.0 range, free from
any organic or psychiatric conditions, no taking any drug
and with normal vital signs, electrocardiogram (ECG),
medical records and physical examination. It was not
allowed to take other drugs during the study.
Sample processing, quantification, and pharmacokinetic
analysis
Sampling was extended for 12 h in the clinical trials
under fasting conditions and for 24 h under fed condi-
tions, as follows: (i) Fasting omeprazole – 21 samples:
predose, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.33,
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3.67, 4, 4.5, 5, 5.5, 6, 7, 8, 10 and 12 h; (ii) fed omepra-
zole - 26 samples: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4,
4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 1 h, 12, 14, 17, 20
and 24 h; (iii) fasting pantoprazole – 14 samples: pre-
dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10 and 12 h; (iv)
fed pantoprazole – 37 samples: predose, 1, 1.5, 2, 2.5, 3,
3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11,
11.5, 12, 12.5, 13, 13.5, 14, 15, 16, 17, 18, 19, 20, 21, 22
and 24 h; (v) fasting rabeprazole – 15 samples: predose,
1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10 and 12 h; (vi) fed
rabeprazole – 37 samples: predose, 1, 1.5, 2, 2.5, 3, 3.5,
4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5,
12, 12.5, 13, 13.5, 14, 15, 16, 17, 18, 19, 20, 21, 22 and
24 h.
Sample processing, genotyping for CYP2C19 and drug
quantification were performed according to Román et al.
[5]. As the formulations were bioequivalent, we used the
mean concentrations obtained after receiving both test
and reference formulations to calculate the pharmacoki-
netic parameters of each subject. Pharmacokinetic param-
eters were estimated from the plasma concentration–time
data by non-compartmental analysis (WinNonlin Profes-
sional, version 2.0., Pharsight Corporation, USA) as re-
ported by Román et al. [5].
Data analysis
WinNonLin Professional software version 2.0 was used
for the statistical analysis. Pharmacokinetic parameters
were log-transformed, and AUC and Cmax were adjusted
for dose and weight. The values of pharmacokinetic pa-
rameters were expressed as mean ± standard deviation.
An analysis of the variance (ANOVA) test was applied
to calculate the statistical significance of the differences
in pharmacokinetic parameters considering the factors
sex and food condition; in the model for omeprazole the
factor subject was also included. The 90% confidence
interval of the ratio of geometric means between fed and
fast conditions were calculated. To avoid the influence
of CYP2C19 polymorphisms, this analysis was repeated




We analyzed 186 volunteers (95 men and 91 women).
Average age was higher in the omeprazole study
(26.73 ± 5.74 years) than in the pantoprazole study
(23.81 ± 3.18 years, p ≤ 0.001) and the rabeprazole study
(24.62 ± 3.78 years, p ≤ 0.05). Weight was similar in the
three drugs clinical trials (66.25 ± 11.27 kg for pantopra-
zole, 68.21 ± 13.07 kg for rabeprazole, and 67.69 ± 12.78
kg for omeprazole).
Thirty five subjects from omeprazole study accepted
CYP2C19 genotyping, being 16 *1/*1, 7 *1/*2, 1 *2/*2, 10
*1/*17 and 1 *2/*17. In the case of pantopazole, 33 sub-
jects were genotyped in the fasting trial (14 *1/*1, 6 *1/*2,
11 *1/*17 and 2 *17*17) and 36 in the fed trial (14 *1/*1, 6
*1/*2, 14 *1/*17, 1 *17/*17 and 1 *2/*17). In the rabepra-
zole studies, 30 subjects were genotyped in the fasting trial
(14 *1/*1, 5 *1/*2, 9 *1/*17 and 2 *2/*17) and 22 in the fed
trial (9 *1/*1, 4 *1/*2, 8 *1/*17 and 1 *2/*17).
Role of food in the pharmacokinetics of PPIs
The effect of food on the pharmacokinetics of omepra-
zole, pantoprazole, and rabeprazole is shown in Table 1.
Mean plasma concentration-time profiles are depicted in
Fig. 1.
Under fasting conditions, Tmax was significantly
reached earlier for omeprazole (2 h) than for pantopra-
zole (3 h) and rabeprazole (3.7 h) (p ≤ 0.001) (Fig. 2a). In
addition, Tmax was also significantly reached earlier for
pantoprazole than for rabeprazole (p ≤ 0.001).
Tmax was delayed when only pharmacokinetic data after
food intake were taken into consideration: Tmax for omep-
razole (4.9 h) was earlier than for pantoprazole (7 h) and
rabeprazole (7.2 h) (p ≤ 0.001), but no differences were
found between pantoprazole and rabeprazole (Fig. 2a).
The administration of omeprazole with food delayed
its mean Tmax by about 3 h (p ≤ 0.001) and increased the
variability of Tmax, with a range of 1–3.5 h under fasting
conditions and a range of 1–17 h under fed conditions.
Under fed conditions, omeprazole AUC and Cmax were
12 and 27% lower, respectively (p ≤ 0.001), and half-life
was 15% higher (p ≤ 0.05 and p ≤ 0.001, respectively).
Food delayed the pantoprazole Tmax by around 4 h
(p ≤ 0.001), with a range of 1.5–5 h under fasting condi-
tions and 1–21 h under fed conditions. In addition, pan-
toprazole AUC was 33% lower (p ≤ 0.001) under fed
conditions (Fig. 2b).
Food also increased the rabeprazole Tmax by about 3.5
h (p ≤ 0.001), with a range of 2–7 h under fasting condi-
tions and 3–20 h under fed conditions. The rabeprazole
Cmax and half-life were 21 and 66% higher under fed
conditions (p ≤ 0.05 and p ≤ 0.001, respectively).
When only subjects with CYP2C19*1/*1 were taken
into account (n = 82; 31 omeprazole, 28 pantoprazole,
and 23 rabeprazole) similar results were obtained: food
increased variability and delayed Tmax by 2.7 h for panto-
prazole (from 3 to 5.7 h, p ≤ 0.001), 3 h for omeprazole
(from 1.8 to 4.9 h, p ≤ 0.001), and 5.2 h for rabeprazole
(from 3.9 h to 9.1 h, p ≤ 0.001) (Table 2). In addition,
under fed conditions, the rabeprazole half-life was higher
(p ≤ 0.05); and the omeprazole AUC and Cmax were
lower (p ≤ 0.05 and p ≤ 0.01, respectively).
Role of sex in the pharmacokinetics of PPIs
There were no differences in the pharmacokinetic
parameters between men and women for the three
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drugs, but sex affected the pantoprazole Tmax under
fed conditions that was higher in women (p ≤ 0.05)
(Table 1).
When only CYP2C19*1/*1 subjects are taken into
account, under fed conditions rabeprazole AUC was
higher (p ≤ 0.05) and half-life was lower in women
(p ≤ 0.05).
Discussion
Our data showed that food delays the absorption of all
PPIs by a mean of 3–4 h. This finding agrees with those
of previous studies for esomeprazole [13], tenatoprazole
[14], and rabeprazole [15].
The effectiveness of the initial antisecretory action of a
PPI depends on factors such as timing in relation to
Fig. 1 Mean plasma concentration-time profiles of (a) pantoprazole, (b) rabeprazole and (c) omeprazole, when administered under fed
and fasting conditions
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meals [16]. Because of their short half-lives, PPIs are best
administered before a meal or ideally after a period of
fasting [17] to ensure that the proton pumps are max-
imally activated when the drug is available in plasma
[16]. Nevertheless, as shown in a study on physician
prescription patterns, there is much confusion about the
optimal time to take a PPI in relation to meals [17].
AUC is the primary pharmacokinetic parameter to de-
termine the antisecretory effect on omeprazole that is
independent on Cmax [18]. Meals with a high fat content
Fig. 2 Differences in PPI Tmax (a) and AUC (b) when administered under fed and fasting conditions. ***p < 0.001. Bars represented as mean and
standard deviation
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slow gastric emptying [19], thus delaying absorption of
the drug and lowering AUC and Cmax values [20]. In our
opinion, a low-fat breakfast would also influence PPI ab-
sorption, however, the effect might be less noticeable
and maybe not clinically relevant. In this regard, the
presence of food has been reported to reduce the Cmax
and AUC of omeprazole [21] and esomeprazole [13].
Thomson et al. found that the evening meal reduced the
tenatoprazole AUC compared with evening administra-
tion of the drug under fasting conditions [14]. Our data
are in accordance with this finding, since the pantopra-
zole AUC and omeprazole AUC and Cmax were signifi-
cantly lower under fed conditions. A decrease in AUC
higher than 20% may be clinically relevant and can influ-
ence the effect on acid secretion. However, it should be
further evaluated in chronic PPI treatment, since a
single-dose study is not the best approach to established
the actual correlation.
However, food increased rabeprazole Cmax and half-
life. The metabolism of omeprazole, pantoprazole, and
rabeprazole is mediated mainly by CYP2C19 and
CYP3A4 [22], but the involvement of CYP3A4 is higher
for rabeprazole. The inhibition of CYP3A4 by food may
be associate to a lower first-pass metabolism that may
explain the increase in Cmax and half-life when rabepra-
zole is administered under fed conditions. Although the
meals given to the volunteers did not contain grapefruit
or other known CYP3A4 inhibitors, other components
of food could also inhibit in some extent CYP3A4.
Moreover, the difference in Cmax can also be due to dif-
ferent genetic profile in subjects participating in the fed
and fast studies, since it disappears when considering
only CYP2C19*1/*1 subjects (see Table 2).
Clearance and volume of distribution cannot be prop-
erly calculated when the drug is administered by oral
route and we can only calculate these parameters ad-
justed for bioavailability. In this way, Cl/F is calculated
as dose/AUC, and Vd/F as Cl/Ke. So, the differences
found in these parameters may reflect the differences in
bioavailability when the drug is administered with food.
Food increased variability in Tmax for all 3 drugs,
delaying absorption around 3 to 4 h and until 20 h in
some subjects. This can be related with the different ef-
fect of a high-fat meal on stomach empting and CYP3A4
inhibition in each subject.
Food intake increases the gastric pH that activates
ATPase molecules, thus resulting in acid secretion [2].
PPIs require secretion of acid for activation and binding
to ATPase molecules [13]; therefore, food may affect the
pharmacokinetics and pharmacodynamics of PPIs [3, 4].
Because of the direct relationship between plasma
AUC and the antisecretory effects of PPIs [23, 24], it
might be expected that administration of PPIs with food
would decrease acid suppression. In this respect,
Andersson et al. reported that inhibition of intragastric
acid secretion by esomeprazole increases with higher ex-
posure (AUC) [23]. Therefore, a higher AUC correlates
with higher efficacy. For this reason, in the case of panto-
prazole and omeprazole, since food decreases the AUC, it
would be better to administer these drugs under fasting
conditions. However, Iwata et al. observed that pre-dinner
administration of PPIs could increase their efficacy in pa-
tients with gastroesophageal reflux disease [25].
Since findings are contradictory, some authors state
that food did not affect PPIs. In their review, Swan et al.
reported that the bioavailability of rabeprazole was not
influenced by co-ingestion of food [26]. Junghard et al.
found that food decreased AUC and Cmax but had no ef-
fect on the percentage of time that intragastric pH was
> 4.0, because of the more extended plasma concentra-
tion profile (longer duration with esomeprazole) [24].
Huber et al. observed that concomitant intake of a
standard breakfast with pantoprazole (40 mg) had no ef-
fect on bioavailability [27]. In this regard, our study
sheds light to this controversy, since we found a clear in-
fluence of food intake in omeprazole, rabeprazole and
pantoprazole pharmacokinetic parameters.
In our opinion, based on our results, omeprazole and
pantoprazole drug label should include the following
sentence: “As food delays the absorption of PPIs around
3 to 4 hours and decreases their bioavailability, it would
be better to administer these drugs under fasting
conditions.”
Finally, the effect of sex was analysed because all fac-
tors that may influence pharmacokinetics must be taken
into account. However, the differences found in AUC
for rabeprazole are very small (around 5%), so it is not
expected to be related to a different clinical effect.
Conclusion
In conclusion, administration of PPIs with food delays
absorption around 3 to 4 h and increases their variability.
Food also decreases oral exposure of omeprazole and
pantoprazole. Consequently, it would be better to ad-
minister PPIs under fasting conditions to improve their
efficacy.
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